Логин: Пароль: ?
Продукты питания Ткань, одежда, обувь, постельное белье, текстиль Строительные материалы Бумага, пластик, промтовары Биотопливо Продукция для сельского хозяйства, зоотовары Косметика, средства гигиены Медицинские товары и препараты, лекарства Иное


Наши партнеры:




Where to look for cannabis seed high in cannabidiol


Growing and processing cannabis containing an increased amount of cannabidiol is a super profitable event. According to American and Canadian estimates, European varieties containing 1-3% of CBD, theoretically, can bring about $ 37 thousand per hectare. With a CBD content of up to 6%, the return on investment rises to almost $ 225 thousand, to 12% - $ 450 thousand.
It is necessary to immediately distinguish between the fact that marijuana and medical varieties of cannabis are not the same thing. In particular, during the Cannabinoid Therapy round table, the head of the company who created drugs based on drug-free cannabinoids in the EU claimed that “If the content of tetrahydrocannabinol (THC) is above 1%, the drugs stop working. The effect of THC "extinguishes" the therapeutic effect of other cannabinoids. " Therefore, in this material we will talk about hemp varieties, in which the amount of psychoactive THC is insignificant, at the same time, the percentage of cannabidiol is sufficient for the vegetable raw materials to have a clearly visible therapeutic effect.
So, if you are interested in certified technical hemp seeds with a high content of cannabidiol (CBD), it does not make sense to look for them in the EU. In the database of plants allowed for cultivation on the territory of the European Union, cannabis varieties with a high content of CBD are not registered, and European breeders have practically no incentive to develop such hybrids, as at the moment for European countries the number of tetrahydrocannabinol not exceeding 0.2%.
European varieties of technical hemp are developed and recorded for cultivation in order to obtain the maximum yield of seeds or volume of fiber. This work is carried out to serve primarily the economic sectors associated with the historically established traditions of hemp breeding on the continent and the already established areas of modern development of industries that have been reviving since the late 90s of the twentieth century (grocery, cosmetic, construction, textile, biocomposite, energy, zoo business etc.).
Direct correlation between TGC and CBD
Given the rapid growth of the global market for cannabidiol, European breeders only in recent years have paid attention to the need for plant breeding containing an increased amount of drug-free cannabinoids. Since the content of CBD is directly proportional to THC in the plant, and in Europe the limit of tetrahydrocannabinol is limited to 0.2%, the selection base itself has a relatively low percentage of cannabidiol in its composition. In addition, increased attention to the creation of varieties with the maximum number of seeds and fiber, until recently, did not imply the task of increasing and stabilizing a significant amount of cannabidiol in new varieties. Those. European breeders for quite a long time had to deal with the prevailing stereotypes and, most importantly, prepare the basis for the creation of exactly therapeutic varieties of technical hemp.
That is why the European seed market contains seeds with a high content of CBD, produced by cannabis seed banks, which themselves confuse the consumer and do not have a therapeutic effect for the reasons indicated at the above Round Table. It should also be borne in mind that this seed is sold mainly as collectibles and such varieties did not go through any registration procedure in the relevant EU regulatory documents. Those. There are no guarantees of exactly how much cannabidiol is in the widely advertised “cannabinoid varieties of marijuana”, and among other things, either in the quality or stability of this seed material.
Varieties created in the USA and Canada
While in the economically developed countries of North America several varieties of technical cannabis with a high cannabidiol content, which practically comply with European restrictions on the amount of THC, were developed, American and Canadian breeders do not consider the registration of these varieties in the EU to be economically feasible a lengthy and expensive process that requires significant investments from North American breeders). Among other things, breeders in Canada and the United States earn excellent money by bringing to the market varieties of cannabis, which are more expedient to grow in greenhouses / closed premises, and they are not interested in creating hybrids grown on areas of thousands of hectares.
In other words, investments in the development and / or registration of technical cannabis varieties with high CBD content that meet EU certification standards and market needs are considered unacceptable for North American breeders in spite of the profits currently received from the sale of finished products containing CBD.

Growing and laneWorking cannabis with a high amount of cannabidiol is a super profit. According to American and Canadian estimates, European varieties containing 1-3% of CBD, theoretically, can bring about $ 37 thousand per hectare. With a CBD content of up to 6%, the return on investment rises to almost $ 225 thousand, to 12% - $ 450 thousand.
That is why individual growers in the EU actually work as marijuana producers, acquiring and cultivating non-certified seeds with a high content of CBD and are engaged in essentially illegal plant growing operations that are competitive in today's rapidly developing cannabinoid market.
Breeders of our country have created technical hemp varieties of therapeutic orientation, which demonstrate their extreme efficacy in the treatment of neurodegenerative, oncological, as well as other serious, including chronic diseases. The profitability of their cultivation is no less than that which North American specialists considered and basic figures were voiced during the Cannabinoid Therapy round table. For our country, the main problem of the impossibility of using therapeutic properties is the absence of varieties, which are not inherent in Europe, and not the regulation of the regulatory framework that does not allow the therapeutic properties of technical hemp to be used in Ukraine.
How prey on the hype of the market
In order to remain competitive in the rapidly developing cannabinoid market, Swiss, American, Canadian and Chinese cannabis farmers are looking for uncertified, but with maximum productivity, CBD seeds, usually obtained from marijuana breeders or seed banks, which disclaim responsibility for what they are selling. For the most part, unstabilized hybrids or incomprehensible plants that do not have a therapeutic effect are sold on the market.
Commentary of the «Ukrainian Industrial Hemp Association»
Due to the fact that currently drug-free cannabinoids have become the main trend of the cannabis market, and manufacturers from around the world profit from the lack of certified technical hemp varieties in Europe, there are no established breeding schemes and there are regulatory restrictions for the production of varieties with a high content of CBD - European the market has actually stalled in its development. Structural weaknesses reduce Europe’s potential contribution to the global re-emergence of cannabis, and Europe’s business position in global cannabis is lost.
Considering that the main market for export of hemp products in Ukraine is the European market, it can be stated with considerable certainty that if for quite a short time the regulatory framework of our country regarding the possibility of using the therapeutic possibilities of technical hemp will not be regulated derived in national breeders of the “technical hemp” variety of therapeutic orientation will become the property of the European, Asian about the North American markets. In the same case, if national breeders find it impossible to continue their further work on the territory of our country, Ukraine will lose the intellectual resource capable of creating exclusive products, which have no analogues in the world. In fact, the country will forever lose its own ability to form a national market for pharmaceutical products from local hemp raw materials and for a very long period of time will become dependent on low-quality pharmacological preparations based on synthetic cannabidiol.
Все объявления »